Results 181 to 190 of about 554,810 (355)

Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer

, 1993
P. Grantley Gill, Val Gebski, R. Snyder, I. Burns, John A. Levi, Michael Byrne, Alan S. Coates   +6 more
openalex   +1 more source

Concurrent Tamoxifen (TAM) + Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Versus Tam + Delayed Cef After Six Months of Endocrine Therapy in Metastatic Breast Cancer a Randomized Trial from the Danish Breast Cancer Cooperative Group (DBCG) [PDF]

, 1996
Per Pfeiffer, Carsten Rose, Bent Ejlertsen, Michael Andersson, D. Pedersen, Henning T. Mouridsen   +5 more
openalex   +1 more source

Microphysiological Systems of Lymphatics and Immune Organs

Advanced Healthcare Materials, EarlyView.
This review surveys recent progress in engineering lymphatic microenvironments and immune organoids within microphysiological systems, emphasizing innovative strategies to recreate the biochemical and biophysical complexity of native lymphatic tissues.
Ishita Jain, Ankur Singh, Andrés J. García   +2 more
wiley   +1 more source

Mandibular Metastatic Breast Cancer: A Rare Case Report with Diagnostic Challenge. [PDF]

J Dent (Shiraz)
Mehdizadeh M, Lotfi A, Atarbashi-Moghadam S, Eftekhari Moghadam P.   +3 more
europepmc   +1 more source

Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer

, 1990
SM Alam, Philippa Whitford, William Cushley, W.D. George, AM Campbell   +4 more
openalex   +1 more source

Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs

Advanced Healthcare Materials, EarlyView.
Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner, Stefan Keim, Soheil Haddadzadegan, Odile Fernandez Romero, Katrin Zöller, Gabriel Stern, Ilaria Cesi, Krum Kafedjiiski, Andreas Bernkop‐Schnürch   +8 more
wiley   +1 more source

AMCP Market Insights: Navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer. [PDF]

J Manag Care Spec Pharm
Flavin B, Wolff D, Bobolts L, Gandhi G, Haumschild R, Iyengar N, Kobernick M, Lich R, Shah B.   +8 more
europepmc   +1 more source

Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?

, 1993
AR Dixon, Lee Jackson, Stephen Chan, R.A. Badley, RW Blamey   +4 more
openalex   +1 more source

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [PDF]

, 1999
Yutaka Tokuda, Toru Watanabe, Yasushi Omuro, Masashi Ando, Noriyuki Katsumata, Akihisa Okumura, Masateru Ohta, Hirofumi Fujii, Yosuke Sasaki, Toshiro Niwa, Tomoo Tajima   +10 more
openalex   +1 more source

Digitonin‐Loaded Nanoscale Metal–Organic Framework for Mitochondria‐Targeted Radiotherapy‐Radiodynamic Therapy and Disulfidptosis

Advanced Materials, EarlyView.
A mitochondria‐targeted cationic nanoscale metal organic framework shows strong radiotherapy‐radiodynamic therapy effects and selectively releases digitonin in acidic tumor microenvironments to induce disulfidptosis of cancer cells and downregulate immune checkpoints in cancer and T cells, thereby eliciting strong antitumor immunity to effectively ...
Wenyao Zhen, Yingjie Fan, Tomas Germanas, Langston Tillman, Jinhong Li, Abigail L. Blenko, Ralph R. Weichselbaum, Wenbin Lin   +7 more
wiley   +1 more source